Clinical Trials | December 18, 2025
The combination also outperformed chemotherapy on another important secondary endpoint
Patients with BRCA mutations often face aggressive disease and poor prognosis
Hansoh Pharma will receive an upfront payment in the low double-digit millions
Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion
India plays a critical role in Bristol Myers Squibb’s global strategy
The company operates a chain of mid-sized multi-speciality hospitals
The state-of-the-art facility is a 350-bedded, multi-specialty tertiary care hospital
The approval of Nuzolvence (zoliflodacin) follows a collaborative development effort with the Global Antibiotic Research and Development Partnership
This launch is part of the company's strategy to expand its nutraceutical portfolio
Subscribe To Our Newsletter & Stay Updated
